down arrow

AnaptysBio, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0327241065
USD
43.30
2.4 (5.87%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Alpine Immune Sciences, Inc.
AnaptysBio, Inc.
Alector, Inc.
Entrada Therapeutics, Inc.
Dyne Therapeutics, Inc.
Vera Therapeutics, Inc.
Enliven Therapeutics, Inc.
Anavex Life Sciences Corp.
4D Molecular Therapeutics, Inc.
Allogene Therapeutics, Inc.
HilleVax, Inc.
Why is AnaptysBio, Inc. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 0.61% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -10.25
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 72.20%, its profits have risen by 9.8%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is AnaptysBio, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
AnaptysBio, Inc.
96.82%
0.88
86.36%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
46.91%
EBIT Growth (5y)
0.61%
EBIT to Interest (avg)
-10.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.13
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
20.47
EV to EBIT
-6.87
EV to EBITDA
-7.04
EV to Capital Employed
26.06
EV to Sales
6.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-379.46%
ROE (Latest)
-413.34%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
NET SALES(HY)

At USD 50.03 MM has Grown at 175.67%

NET PROFIT(HY)

Higher at USD -77.96 MM

ROCE(HY)

Highest at 0%

RAW MATERIAL COST(Y)

Fallen by -2.91% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -180.51 %

DEBTORS TURNOVER RATIO(HY)

Highest at 8.1 times

-13What is not working for the Company
NET SALES(Q)

At USD 22.26 MM has Fallen at -20.4%

CASH AND EQV(HY)

Lowest at USD 605.65 MM

INTEREST(Q)

Highest at USD 19.61 MM

Here's what is working for AnaptysBio, Inc.
Net Profit
Higher at USD -77.96 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -180.51 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 8.1 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -2.91% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for AnaptysBio, Inc.
Net Sales
At USD 22.26 MM has Fallen at -20.4%
over average net sales of the previous four periods of USD 27.97 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Interest
Highest at USD 19.61 MM
in the last five periods and Increased by 8.55% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv
Lowest at USD 605.65 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."